Xtandi competitor ARN-509 "still has many outstanding questions/hurdles," JPMorgan's Geoff...
Xtandi competitor ARN-509 "still has many outstanding questions/hurdles," JPMorgan's Geoff Meacham says, reiterating an Overweight rating on shares of Medivation (MDVN -9.3%) which are currently in a tailspin following JNJ's acquisition of Aragon (I, II). Meacham acknowledges that Aragon's cause (both from a legal and development perspective) will be helped by JNJ's substantial resources, but notes that early stage prostate cancer agents face "significant clinical, regulatory, and commercial hurdles."
From other sites
at Zacks.com (Thu, 3:20PM)
Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express Scripts - Press Releasesat Zacks.com (Mar 18, 2015)
at Zacks.com (Feb 27, 2015)
at Zacks.com (Feb 26, 2015)
at Investor's Business Daily (Feb 26, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs